선택 적 CB 2 수용체 작용 제 는 동물 모델 에서 급성 , 만성 , 염증 성 및 신경 병증 성 통증 반응 을 억제 함 에 따라 , 급 성 및 만성 통증 의 치료 에 유망 한 것 으로 나타났 다 ( 참조 : Malan TP , Jr . , Ibrahim MM , Lai J , Vanderah TW , Makriyannis A and Porreca F , CB 2 cannabinoid receptor agonists : pain relief without psychoactive effects ? , Current Opinion in Pharmacology , ( 2003 ) , 3 ( 1 ) , 62 - 67 ; Ibrahim MM , Deng H , Zvonok A , Cockayne DA , Kwan J , Mata HP , Vanderah TW , Lai J , Porreca F , Makriyannis A and Malan TP , Jr . , Activation of CB 2 cannabinoid receptors by AM 1241 inhibits experimental neuropathic pain : Pain inhibition by receptors not present in the CNS , Proceedings of the National Academy of Sciences of the United States of America , ( 2003 ) , 100 ( 18 ) , 10529 - 10533 ; and , Burns TL and Ineck JR , Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain , Annals of Pharmacotherapy , ( 2006 ) , 40 ( 2 ) , 251 - 260 ) .